CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.

Janina GrauleKristin UthElia FischerIrene CentenoJosé A GalvánMicha EichmannTilman T RauRupert LangerHeather DawsonUlrich NitschePeter TraegerMartin D BergerBeat SchnürigerMarion HädrichPeter StuderDaniel InderbitzinAlessandro LugliMario P TschanInti Zlobec

Published in: Clinical epigenetics (2018)

CDX2 loss is an adverse prognostic factor and linked to molecular features of the serrated pathway. RNA/protein expression is restored in CDX2 low-expressing CRC cell lines by demethylation and HDAC inhibition. Importantly, our data underline HDAC4 and HDAC5 as new epigenetic CDX2 regulators that warrant further investigation.

Keyphrases

prognostic factors
dna methylation
histone deacetylase
gene expression
transcription factor
genome wide
electronic health record
emergency department
big data
machine learning
single molecule
data analysis
adverse drug